Noxopharm Limited. ABN 50 608 966 123 Suite 71, 159 Ridgecrop Drive, Castle Hill, NSW 2154, Australia FDA feedback supports SOF-SKN™ Phase II plans Highlights • FDA has provided constructive feedback which was supportive of Noxopharm’s planned approach for a Phase II clinical trial for...